Dayvigo (Lemborexant) Compassionate Use, Expanded Access, and How to Pay Less

What Compassionate Use and Expanded Access Actually Mean for Dayvigo

Compassionate use and expanded access are two names for the same FDA pathway: a mechanism that lets a patient receive an investigational drug outside of a clinical trial, usually when no approved alternative exists and the illness is serious or life-threatening. The FDA expanded access regulations at 21 CFR Part 312, Subpart I govern this process.

Here is the direct answer for Dayvigo specifically. Lemborexant was approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. Because it is already an approved, commercially available drug, a formal compassionate use or expanded access investigational new drug (IND) application is generally not the right pathway for most women seeking access. Expanded access exists primarily for drugs not yet approved, or for approved drugs sought for a use that has no approved alternative.

What women searching for "Dayvigo compassionate use" are almost always actually looking for is one of three things: a patient assistance program, a discount program, or help accessing the drug when insurance denies coverage. All three are addressed below.

When Expanded Access Could Still Apply

There is one scenario where expanded access remains relevant even for an approved drug. If your clinician wants to prescribe lemborexant for a use not covered by its FDA label, such as a specific pediatric age group or a comorbidity not studied in the key trials, a single-patient expanded access IND submitted by your physician to the FDA is possible. Eisai must also provide the drug. As of early 2026, Eisai has not published an open named-patient or expanded access protocol for lemborexant beyond its approved indication.

If you or your clinician believe you have a medically compelling case, the FDA's expanded access navigator at 1-855-543-3784 is the starting point. Your physician completes FDA Form 3926, contacts Eisai's medical information line (1-888-274-2378), and files with the FDA. The FDA review of single-patient emergency requests can take as little as 24 hours.

The Insomnia-Severity Reality That Makes Cost So Pressing

Insomnia disorder affects roughly 30% of adults, with women experiencing insomnia at nearly 1.4 times the rate of men, a gap that widens sharply during perimenopause. A 2018 study in Menopause found that over 50% of perimenopausal women reported clinically significant sleep disturbance. When a drug like lemborexant costs $400 to $500 per month out of pocket, the access problem is very real, even though it is not technically a compassionate use situation.

How Dayvigo Works: Sex-Specific Pharmacology You Should Know

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks orexin-1 (OX1R) and orexin-2 (OX2R) receptors. Orexin peptides promote wakefulness; blocking them lets sleep occur more naturally compared with older sedative-hypnotics that broadly suppress the central nervous system.

Why This Mechanism Matters Specifically for Women

The orexin system does not operate identically across sexes. Estrogen modulates orexin neuron activity. Animal data suggest orexin signaling shifts across the estrous cycle, and clinical observations support that insomnia in perimenopause involves dysregulated arousal signaling, not just hot-flash-related awakenings. The SUNRISE 1 and SUNRISE 2 trials, the key studies supporting FDA approval, enrolled approximately 60% women, which is one of the stronger sex-balanced enrollment records for a sleep drug. SUNRISE 2, a 12-month study, showed lemborexant 5 mg reduced subjective sleep onset latency by a mean of 29.0 minutes versus 18.4 minutes for placebo at month 1, with effects maintained through month 12.

Pharmacokinetic Sex Differences

Women metabolize lemborexant slightly differently than men. The drug is primarily metabolized by CYP3A4. In the prescribing information pharmacokinetics section, Cmax in women is approximately 28% higher than in men at equivalent doses. The prescribing information notes that no dose adjustment is required based on sex alone, but this PK difference means women may experience more pronounced next-morning sedation, particularly at the 10 mg dose. The FDA label carries a specific warning about next-day driving impairment.

Dosing Across Life Stages

The approved starting dose is 5 mg at bedtime, no more than once per night, with at least 7 hours remaining before planned awakening. The dose may be increased to 10 mg if the 5 mg dose is tolerated but not effective. For women in perimenopause or postmenopause who are also taking CYP3A4 inhibitors (certain antifungals, some antiretrovirals), the dose ceiling drops to 5 mg. Common hormonal medications like low-dose vaginal estrogen do not significantly interact, but oral conjugated equine estrogen can modestly affect CYP3A4 activity, so let your prescriber know everything you take.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Dayvigo is not recommended during pregnancy. This section is mandatory reading if you are pregnant, trying to conceive, or not using reliable contraception.

Pregnancy Data

Lemborexant has no adequate, well-controlled studies in pregnant women. Animal reproduction studies showed increased embryo-fetal mortality and decreased fetal body weight at doses producing maternal exposures approximately 60 times the maximum recommended human dose of 10 mg. The drug does not carry a formal legacy FDA pregnancy letter category (drugs approved after June 2015 use the PLLR labeling system instead), but the label language reads as "avoid use in pregnancy unless benefit clearly outweighs risk," which in practice means it should not be used.

If you discover you are pregnant while taking lemborexant, stop the drug and contact your obstetric provider. Insomnia during pregnancy is very common, and safer alternatives exist, including cognitive behavioral therapy for insomnia (CBT-I), which ACOG recognizes as first-line treatment for chronic insomnia in pregnant women, and low-dose doxylamine, which has human safety data in pregnancy.

Lactation

There are no human data on lemborexant transfer into breast milk. Animal lactation studies have not been reported in the public label. Because orexin receptor antagonists have lipophilic properties that suggest potential for milk transfer, and because a breastfed infant's CNS is highly sensitive to sedating agents, the label advises against use during breastfeeding. If you are postpartum and struggling with sleep, discuss CBT-I or short-term use of a drug with more lactation safety data (such as low-dose melatonin or certain antihistamines used briefly) with a women's-health provider before returning to lemborexant.

Contraception Requirement

Lemborexant is not classified as a teratogen requiring mandatory contraception in the way that isotretinoin or valproate are. There is no FDA-mandated risk evaluation and mitigation strategy (REMS) for contraception. However, given the animal fetal harm data, women of reproductive potential who are sexually active should use reliable contraception while on this drug and discuss pregnancy planning with their prescriber before discontinuing contraception.

Every Real Option for Getting Dayvigo at Lower Cost

Below is a ranked framework WomanRx developed for assessing Dayvigo access options, ordered from lowest to highest barrier for most women.

Tier 1: Pharmacy Discount Cards and Apps (Zero Eligibility Requirements)

GoodRx, RxSaver, NeedyMeds, and the Blink Health pharmacy network all offer discounted pricing on lemborexant. Prices vary by pharmacy and zip code, but GoodRx coupons have consistently brought the 30-tablet, 5 mg supply to the $120 to $200 range at certain pharmacies in 2025, compared with the $400 to $500 retail price. You do not need to be uninsured to use these cards; many women with insurance find that a discount card beats their copay tier for non-preferred brand drugs.

How to use: Go to GoodRx.com, search "lemborexant," enter your zip code, and show the pharmacy the coupon code at pickup. You cannot combine a GoodRx coupon with Medicare or Medicaid.

Tier 2: HSA and FSA Payment

Yes. Dayvigo is eligible for payment with a Health Savings Account (HSA) or Flexible Spending Account (FSA) when purchased with a valid prescription. The IRS defines qualified medical expenses to include prescription drugs, and lemborexant is a Schedule IV prescription drug. The practical implication is that you pay with pre-tax dollars, reducing your effective out-of-pocket cost by your marginal tax rate, typically 22% to 32% for many insured working women.

Use your HSA/FSA debit card directly at the pharmacy. If you pay out-of-pocket first, save the receipt and submit for reimbursement through your plan administrator.

Tier 3: Eisai Patient Assistance Program

Eisai operates Eisai's Accessibility and Assistance for Patients (EAP), which provides Dayvigo at no cost to eligible patients. Eligibility is income-based. As of 2025, the general criteria for brand-name manufacturer assistance programs of this type are:

• US resident with valid prescription
• No insurance coverage for the specific drug, or coverage gap (donut hole, prior auth denial)
• Household income typically at or below 400% to 600% of the federal poverty level (Eisai's specific threshold: contact their program directly, as thresholds change)

To apply, your prescriber's office typically submits paperwork on your behalf. Call Eisai directly at 1-888-274-2378 or visit their patient support portal. Processing can take two to four weeks, so plan ahead. Free-drug programs like this one do not count as insurance and are not reportable as income.

Tier 4: Manufacturer Copay Card (Insured Patients)

Eisai has historically offered a savings card for commercially insured patients that reduces copays significantly, sometimes to as low as $0 to $30 per fill. These programs are generally not available to patients on Medicare, Medicaid, or other federal programs. Check Eisai's Dayvigo savings information page or ask your pharmacist to look up current offers in their copay database. Copay programs change on a pharmacy benefits cycle, so verify at your next refill.

Tier 5: Insurance Prior Authorization and Appeals

Many insurance formularies place Dayvigo in Tier 3 or Tier 4 (non-preferred brand), requiring prior authorization (PA). Your prescriber submits a PA documenting that you have tried and failed, or cannot tolerate, at least one formulary-preferred sleep agent (often zolpidem or trazodone). If denied, you have the right to an internal appeal and, in most states, an external independent review. The ACA guarantees internal and external appeal rights for non-grandfathered plans.

Document your history. If you have PCOS-related sleep disruption, restless legs syndrome, or a comorbidity that makes sedating antihistamines or benzodiazepines riskier, include that clinical context in the PA. Women with a documented comorbidity that raises the risk-benefit calculus often get stronger PA support.

Tier 6: Telehealth Prescription Plus Pharmacy Optimization

Some women pay less overall by getting their lemborexant prescription through a telehealth visit (eliminating the specialist copay) and then routing to a cash-pay pharmacy with a discount card. The math only works if your prescriber visit cost and discount card pharmacy price together are less than your total cost through insurance. Run the comparison before each 90-day fill.

Who This Drug Is Right For, and Who Should Look Elsewhere

Women Likely to Benefit Most

Women with insomnia disorder characterized by difficulty falling asleep or staying asleep who have tried and not responded adequately to CBT-I, or who need a medication option while CBT-I is being established, are the core indicated population. Lemborexant is one of the few approved sleep drugs with a 12-month controlled trial (SUNRISE 2), making it a stronger choice for women who need ongoing pharmacotherapy rather than purely short-term use.

Perimenopausal and postmenopausal women with hot-flash-unrelated middle insomnia (waking at 2 to 4 AM and being unable to return to sleep) may find dual orexin antagonism particularly relevant, because this phenotype may reflect dysregulated orexin-mediated arousal rather than purely thermoregulatory disruption. The Menopause Society's 2023 position statement on non-hormonal therapies for menopause supports the use of FDA-approved insomnia medications as adjuncts when vasomotor-symptom management does not fully resolve sleep disruption.

Women with a history of substance use disorder may find lemborexant preferable to benzodiazepine-receptor agonists (zolpidem, eszopiclone) because its abuse potential, while still Schedule IV, appears lower in clinical pharmacology studies. The SUNRISE 1 abuse potential substudy showed lemborexant produced less subjective "drug liking" than triazolam 0.25 mg.

Women Who Should Use Caution or Choose an Alternative

• Pregnant women or those actively trying to conceive: Avoid. CBT-I is first-line.
• Breastfeeding women: Insufficient data; avoid until more human lactation data exist.
• Women with narcolepsy: Contraindicated; blocking orexin signaling worsens cataplexy risk.
• Women on strong CYP3A4 inhibitors (ketoconazole, clarithromycin, certain HIV protease inhibitors): The dose ceiling is 5 mg and the drug should be used with caution or avoided.
• Women with severe hepatic impairment: Avoid.
• Adolescent girls under 18: Not approved in this age group; no adequate data.
• Women with significant next-morning driving obligations at 5 AM: The warning about next-morning impairment is real. The FDA specifically advises women not to drive the morning after taking lemborexant 10 mg if they have not had at least 7 hours of sleep.

Sleep Across the Female Life Span: Why Access Matters More Than You Think

Insomnia is not evenly distributed across a woman's life. The National Sleep Foundation's Women and Sleep data show distinct peaks:

• Postpartum: Sleep fragmentation is near-universal, though insomnia disorder (as opposed to situational sleep deprivation) peaks at roughly 30% of postpartum women at six weeks. Lemborexant is not appropriate here given breastfeeding concerns.
• Perimenopause (average onset age 47): Sleep complaints rise sharply. The Study of Women's Health Across the Nation (SWAN) found that insomnia symptoms increased significantly across the menopausal transition, peaking in early postmenopause, independent of hot flash frequency.
• Postmenopause: Chronic insomnia disorder prevalence of 40% to 60% in women over 55 is reported in multiple epidemiological series. This is the life stage where long-term pharmacotherapy is most often clinically justified, and where Dayvigo's 12-month safety data are most directly applicable.

Treating insomnia in these life stages is not trivial. Chronic sleep deprivation in perimenopausal and postmenopausal women is associated with higher cardiometabolic risk, accelerated bone density loss, and increased all-cause mortality. Getting access to an effective, well-tolerated drug for this indication is a women's-health equity issue.

What the Evidence Gap Means for You

Women have historically been enrolled in sleep drug trials, but pharmacokinetic substudies powered for sex differences have been rare. For lemborexant specifically, the SUNRISE trials did include women in the majority, which is better than many predecessors. However, the trials did not stratify results by menopausal status, hormonal therapy use, or menstrual cycle phase. The prescribing information does not address whether lemborexant efficacy or tolerability differs between premenopausal women cycling naturally, perimenopausal women, or postmenopausal women on estrogen therapy.

What this means practically: the prescribing information guidance is extrapolated to all adult women. If you are on menopausal hormone therapy and experience unexpected side effects or unexpectedly strong sedation with lemborexant, that is worth reporting to your clinician and potentially to FDA MedWatch, because the sex-stratified and hormone-status-stratified data simply do not yet exist in the published literature.

Practical Steps to Take This Week

If you need Dayvigo and cost or access is the barrier, here is the sequence that moves fastest:

1. Confirm your prescription is active and written for the dose your prescriber intended (5 mg vs 10 mg matters for cost because the 10 mg tablets are not cheaper per milligram and dose splitting is not recommended for controlled substances).
2. Run your zip code through GoodRx for lemborexant before going to the pharmacy. Prices vary by $100 to $200 across pharmacies in the same city.
3. If insured but with a high Tier 3 copay, ask your prescriber's office to check the Eisai copay card program on the same day as your visit.
4. If uninsured or underinsured, call Eisai's patient support line (1-888-274-2378) and ask specifically about the Eisai Assistance Program, not just the copay card. These are different programs.
5. If you have an HSA or FSA, use that account at checkout. You save your marginal tax rate on every dollar.
6. If your insurer denied coverage, ask your prescriber to file a prior authorization. A documented trial of zolpidem or another preferred agent strengthens the case significantly.

The average commercially insured woman who uses both the Eisai copay card and routes through a preferred-network pharmacy pays under $50 per month for Dayvigo in 2025. That number is within HSA/FSA reach for most women who have those accounts funded.